This study is currently recruiting participants. Verified by Merck, February 2010 Official Title Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice Purpose This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the […]
A Study of V503 in Females 12-26 Years of Age Who Have Previously Received GARDASIL™
V503 is a multi-valent HPV vaccine still under development by Merck & Co.
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women
This study is ongoing, but not recruiting participants. Official Title Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women – The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Detailed Description: The original base protocol was extended. Subjects in the placebo arm […]
Gardasil-European Public Assessment Report
For complete information on Gardasil, as promoted in Europe, you can obtain access to the authorisation details, product information and their assessment history via this link.
Gardasil-Product Information-FDA
Proper Name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant Trade name: Gardasil Manufacturer: Merck & Co., Inc, License #0002 Product Information and Supporting Documents Approval History, Letters, Reviews, and Related Documents – Gardasil